In Vitro: Laduviglusib (1-10 μM, 3 days) reduces the viability of the ES-D3 cells with an IC50 of 4.9 μM. Laduviglusib (5 μM, 48 h) activates the canonical Wnt-pathway in ES-D3 cells and ES-CCE cells. Laduviglusib (3 μM, 4 days) inhibits ES cell differentiation into neural cells. Laduviglusib (1 μM, 2 weeks) inhibits adipogenesis by blocking induction of C/EBPα and PPARγ in 3T3-L1 preadipocytes. Laduviglusib (2.5 μM, 24 h) protects Lgr5+ cells against radiation-induced apoptosis.
In Vivo: Laduviglusib (30 mg/kg, p.o ) rapidly lowers plasma glucose. Laduviglusib (2 mg/kg, i.p.) protects mice against radiation-induced lethal GI injury.